Oropharyngeal ca: IMRT spares salivary glands

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 10
Volume 17
Issue 10

BOSTON-A multicenter trial that tested intensity-modulated radiation therapy for patients with early-stage oropharyngeal cancer showed a reduction in long-term salivary toxicity while achieving good tumor control, according to research presented at ASTRO 2008.

BOSTON-A multicenter trial that tested intensity-modulated radiation therapy for patients with early-stage oropharyngeal cancer showed a reduction in long-term salivary toxicity while achieving good tumor control, according to research presented at ASTRO 2008.

The phase I/II trial was conducted by the Radiation Therapy Oncology Group (RTOG 0022) and led by Avraham Eisbruch, MD, from the University of Michigan.

A total of 69 patients were entered in the study during a 4-year period at 14 institutions in the U.S. and Canada. Dr. Eisbruch and colleagues reported a 2-year locoregional control rate of 91% and a 49% rate of acute salivary gland toxicity ( greater than or equal to Grade 2).

The rate of salivary gland toxicity dropped to 23% at 1 year and 13% at 2 years.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content